Ecteinascidin-743 (Yondelis®), Aplidin®, and Irvalec®

2011 ◽  
pp. 307-332 ◽  
Keyword(s):  
Ecteinascidin 743

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action

2001 ◽  
Vol 37 (1) ◽  
pp. 97-105 ◽  
Author(s):  
E Erba ◽  
D Bergamaschi ◽  
L Bassano ◽  
G Damia ◽  
S Ronzoni ◽  
...  
Keyword(s):  
Mechanism Of Action ◽  
Marine Compound ◽  
Ecteinascidin 743 ◽  
Unique Mechanism

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair

10.1038/91008 ◽  
2001 ◽  
Vol 7 (8) ◽  
pp. 961-966 ◽  
Author(s):  
Yuji Takebayashi ◽  
Philippe Pourquier ◽  
Drazen B. Zimonjic ◽  
Kentaro Nakayama ◽  
Steffen Emmert ◽  
...  
Keyword(s):  
Nucleotide Excision Repair ◽  
Antiproliferative Activity ◽  
Excision Repair ◽  
Nucleotide Excision ◽  
Ecteinascidin 743

Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity

2001 ◽  
Vol 19 (5) ◽  
pp. 1248-1255 ◽  
Author(s):  
S. Delaloge ◽  
A. Yovine ◽  
A. Taamma ◽  
M. Riofrio ◽  
E. Brain ◽  
...  
Keyword(s):  
Phase I ◽  
Performance Status ◽  
Bone Sarcoma ◽  
Maximum Tolerated Dose ◽  
World Health ◽  
Compassionate Use ◽  
Bulky Disease ◽  
Clinical Resistance ◽  
Ecteinascidin 743 ◽  
Grade 3

PURPOSE: To report the activity of the chemotherapeutic agent ecteinascidin-743 (ET-743) in advanced pretreated sarcoma patients observed during a phase I study and a named-patient basis, compassionate use program. PATIENTS AND METHODS: Twenty-nine pretreated, advanced soft tissue sarcoma (STS) and bone sarcoma patients consecutively seen in our centers were included, 12 from a phase I trial and 17 from a compassionate use program cohort. Patients were treated every 3 weeks at either 1,200 μg/m2 (six patients), 1,500 μg/m2 (the recommended dose, 22 patients), or 1,800 μg/m2 (the maximum-tolerated dose, one patient), given as a 24-hour infusion every 3 to 4 weeks. RESULTS: Fifteen men and 14 women were treated. The median patient age was 46 years (range, 16 to 71 years), with a median World Health Organization performance status of 1 (range, 0 to 2). Twenty-five patients had STS, three had osteosarcoma, and one had Ewing’s sarcoma, and all had progressive disease at accrual. Fifteen patients had bulky disease, and 14 had clinical resistance to anthracyclines. A total of 136 treatment cycles were administered (median per patient, five cycles; range, one to 12 cycles). Transient grade 3 and 4 transaminitis was reported in 24% and 5% of cycles, respectively, grade 3 to 4 neutropenia occurred in 32% of cycles, with concomitant sporadic grade 3 to 4 thrombocytopenia in 5.1% of cycles. Grade 2 to 3 asthenia occurred in 21% of cycles. There were two partial responses (PRs) in STS patients and two PRs in osteosarcoma patients. Two minor responses and 10 disease stabilizations were seen. Median duration of response was 10.5 months (range, 2.8 to 15 months), and mean duration of stabilization was 5.2 months. CONCLUSION: ET-743 has activity in advanced, highly pretreated STS and osteosarcoma patients and warrants further trials to establish the extent of its activity in this setting.

scholarly journals In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

2003 ◽  
Vol 89 (12) ◽  
pp. 2305-2311 ◽  
Author(s):  
C Simoens ◽  
A E C Korst ◽  
C M J De Pooter ◽  
H A J Lambrechts ◽  
G G O Pattyn ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Ecteinascidin 743 ◽  
In Vitro Interaction
Sign in / Sign up

Export Citation Format

Share Document